| immatics begins Imprint phase III trial to treat renal cell carcinoma - pharmabiz.com |
|
|
pharmabiz.com We look forward to confirming the positive overall survival data seen in the phase II study as advanced renal cell cancer still has a very high unmet medical need.” Paul Higham, CEO of immatics added: “An overall survival benefit combined with a stable |